Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 5/20 | 0.55 |
| ▸ | MAOB | P27338 | 4/20 | 0.55 |
| ▸ | CALML3 | P27482 | 7/20 | 0.48 |
| ▸ | F10 | P00742 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | SDHA | P31040 | 1/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3832077 | 1.00 | MAOA (0.55) | MAOAMAOBCALML3F10LMNA | |
| SCHEMBL3832952 | 0.88 | F10 (0.50) | MAOAMAOBCALML3F10LMNA | |
| SCHEMBL3832955 | 0.88 | F10 (0.50) | MAOAMAOBCALML3F10LMNA | |
| SCHEMBL3827426 | 0.85 | MAOA (0.61) | MAOAMAOBCALML3F10LMNA | |
| SCHEMBL3832086 | 0.85 | F10 (0.54) | MAOAMAOBCALML3F10LMNA | |
| SCHEMBL3827421 | 0.85 | MAOA (0.61) | MAOAMAOBCALML3F10LMNA | |
| SCHEMBL3831707 | 0.84 | F10 (0.47) | MAOAMAOBCALML3F10LMNA | |
| SCHEMBL8126460 | 0.84 | MAOA (0.55) | MAOAMAOBCALML3F10LMNA | |
| SCHEMBL13607062 | 0.83 | F10 (0.53) | MAOAMAOBCALML3F10LMNA | |
| SCHEMBL3832292 | 0.83 | F10 (0.55) | MAOAMAOBCALML3F10LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318431-A1 | BENZOXAZINONE AND BENZOXAZEPINONE OXAZOLIDINONES AS ANTIBACTERIAL AGENTS | PFIZER INC. | 2009-12-24 | — | — | US | disclosed |
| EP-1987025-B1 | BENZOXAZINONE AND BENZOXAZEPINONE OXAZOLIDINONES AS ANTIBACTERIAL AGENTS | PFIZER PROD INC (US) | 2009-09-16 | — | — | EP | disclosed |
| EP-1987025-A1 | BENZOXAZINONE AND BENZOXAZEPINONE OXAZOLIDINONES AS ANTIBACTERIAL AGENTS | Pfizer Products Incorporated (US) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007093904-A1 | BENZOXAZINONE AND BENZOXAZEPINONE OXAZOLIDINONES AS ANTIBACTERIAL AGENTS | PFIZER PRODUCTS INC. (US) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318431-A1 | BENZOXAZINONE AND BENZOXAZEPINONE OXAZOLIDINONES AS ANTIBACTERIAL AGENTS | HRH2, HRH1, HRH4 | MAOA 1117/4885MAOB 931/4885CALML3 1664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.